N-tert-butyl-6-chloro-3-nitropyridin-2-amine | 1094323-29-1

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: N-tert-butyl-6-chloro-3-nitropyridin-2-amine
• CAS: 1094323-29-1
• 化学式: C₉H₁₂ClN₃O₂
• 分子量: 229.666
• InChiKey: AFIBFUYXTIKWFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-tert-butyl-6-chloro-3-nitropyridin-2-amine 在 吡啶 、 4-二甲氨基吡啶 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 56.0h， 生成 N-[3-({3-tert-butyl-2-[(cyclopropylcarbonyl)amino]-3H-imidazo[4,5-b]pyridin-5-yl}oxy)phenyl]-3-(1-cyano-1-methylethyl)benzamide
  参考文献：
  名称：

  Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds

  摘要：

  To develop RAF/VEGFR2 inhibitors that bind to the inactive DFG-out conformation, we conducted structure-based drug design using the X-ray cocrystal structures of BRAF, starting from an imidazo[1,2-b]pyridazine derivative. We designed various [5,6]-fused bicyclic scaffolds (ring A, 1-6) possessing an anilide group that forms two hydrogen bond interactions with Cys532. Stabilizing the planarity of this anilide and the nitrogen atom on the six-membered ring of the scaffold was critical for enhancing BRAF inhibition. The selected [1,3]thiazolo[5,4-b]pyridine derivative 6d showed potent inhibitory activity in both BRAF and VEGFR2. Solid dispersion formulation of 6d (6d-SD) maximized its oral absorption in rats and showed significant suppression of ERK1/2 phosphorylation in an A375 melanoma xenograft model in rats by single administration. Tumor regression (T/C = -7.0%) in twice-daily repetitive studies at a dose of 50 mg/kg in rats confirmed that 6d is a promising RAF/VEGFR2 inhibitor showing potent anticancer activity.

  DOI：

  10.1021/jm300126x
• 作为产物：
  描述：

  2,6-二氯-3-硝基吡啶 、 叔丁胺 以 四氢呋喃 为溶剂， 以46%的产率得到N-tert-butyl-6-chloro-3-nitropyridin-2-amine
  参考文献：
  名称：

  [EN] HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS
  [FR] DÉRIVÉS AROMATIQUES HÉTÉROBICYCLIQUES ET HÉTÉROAROMATIQUES POUR LE TRAITEMENT DE TROUBLES LIÉS À LA FERROPTOSE

  摘要：

  本申请公开了杂芳和杂双环芳香衍生物化合物和组合物，以及利用所公开的化合物和组合物治疗患者的铁死亡相关疾病和疾病的方法。

  公开号：

  WO2020185738A1

文献信息

• [EN] HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS<br/>[FR] DÉRIVÉS AROMATIQUES HÉTÉROBICYCLIQUES ET HÉTÉROAROMATIQUES POUR LE TRAITEMENT DE TROUBLES LIÉS À LA FERROPTOSE
  申请人：COLLABORATIVE MEDICINAL DEV LLC

  公开号：WO2020185738A1

  公开（公告）日：2020-09-17

  The present application discloses heteroaromatic and heterobicyclic aromatic derivative compounds and compositions, and methods for treating ferroptosis-related disorders and diseases in patients using the compounds and compositions as disclosed herein.

  本申请公开了杂芳和杂双环芳香衍生物化合物和组合物，以及利用所公开的化合物和组合物治疗患者的铁死亡相关疾病和疾病的方法。
• CYCLIN DEPENDENT KINASE INHIBITORS
  申请人：Pfizer Inc.

  公开号：US20190330196A1

  公开（公告）日：2019-10-31

  This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R 1 to R 23 , A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

  这项发明涉及式（I）的化合物或其药学上可接受的盐，其中R基团R1至R23，A，Q，U，V，W，X，Y，Z，n，p和q如本文所定义，以及包含这种化合物和盐的药物组合物，以及使用这种化合物、盐和组合物治疗受试者的异常细胞生长，包括癌症的方法。
• [EN] METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS<br/>[FR] PROCÉDÉS DE PROLONGEMENT DE LA DURÉE DE VIE PAR ADMINISTRATION D'INHIBITEURS DE LA FERROPTOSE
  申请人：COLLABORATIVE MEDICINAL DEV LLC

  公开号：WO2022020150A1

  公开（公告）日：2022-01-27

  Provided herein is a method of extending the lifespan of an organism comprising administering to the organism an effective amount of a ferroptosis inhibitor. Also provided are compositions for extending lifespan comprising ferroptosis inhibitors.

  本文提供了一种延长生物寿命的方法，包括向生物体内施加有效量的铁死亡抑制剂。还提供了包含铁死亡抑制剂的延长寿命的组合物。
• Cyclin dependent kinase inhibitors
  申请人：Pfizer Inc.

  公开号：US10766884B2

  公开（公告）日：2020-09-08

  This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

  本发明涉及式（I）化合物 或其药学上可接受的盐，其中 R 基团 R1 至 R23、A、Q、U、V、W、X、Y、Z、n、p 和 q 如本文所定义；包含此类化合物和盐的药物组合物；以及使用此类化合物、盐和组合物治疗受试者异常细胞生长（包括癌症）的方法。
• HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS
  申请人：Collaborative Medicinal Development, LLC

  公开号：EP3938340A1

  公开（公告）日：2022-01-19